However, the study showed that the JAK2 allelic burden was not associated with the rate of NET formation, and ultimately it did not seem likely that the genetically driven NET formation would translate in the clinical endpoint, such as thrombosis in MPNs, which put their results in contrast to the effects seen by Wolach et al. [100]. The gene discussed is JAK2; the disease is Venous thrombosis.